Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
12.73
-0.71 (-5.28%)
At close: Apr 7, 2026, 4:00 PM EDT
12.78
+0.04 (0.35%)
After-hours: Apr 7, 2026, 4:17 PM EDT
Contineum Therapeutics Employees
Contineum Therapeutics had 51 employees as of December 31, 2025. The number of employees increased by 10 or 24.39% compared to the previous year.
Employees
51
Change (1Y)
10
Growth (1Y)
24.39%
Revenue / Employee
n/a
Profits / Employee
-$1,176,039
Market Cap
475.29M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 51 | 10 | 24.39% |
| Dec 31, 2024 | 41 | 10 | 32.26% |
| Dec 31, 2023 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Lyell Immunopharma | 300 |
| 4D Molecular Therapeutics | 196 |
| Rigel Pharmaceuticals | 174 |
| Entrada Therapeutics | 152 |
| enGene Holdings | 82 |
| Fulcrum Therapeutics | 55 |
| Shattuck Labs | 40 |
| vTv Therapeutics | 26 |
CTNM News
- 25 days ago - Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones - Business Wire
- 5 weeks ago - Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference - Business Wire
- 4 months ago - Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering - Business Wire
- 4 months ago - Contineum Therapeutics Announces Proposed $75.0 Million Public Offering - Business Wire
- 4 months ago - Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference - Business Wire
- 4 months ago - Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value - Benzinga
- 4 months ago - Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - Business Wire